Webinar: LIVE Webinar - Leveraging the Gut Microbiome to Impact Metabolism with Colleen Cutcliffe, PhD and Orville Kolterman, MD by Fullscript / Emerson Ecologics

LIVE Webinar - Leveraging the Gut Microbiome to Impact Metabolism with Colleen Cutcliffe, PhD and Orville Kolterman, MD

Join us on Monday, July 31st at 3pm est for this informative webinar.

Learn from renowned endocrinologist, Dr. Orville Kolterman, and Colleen Cutcliffe, co-founder and CEO of Pendulum Therapeutics as they discuss how the microbiome and certain novel strains, like Akkermansia muciniphila, play a huge role in the gut-metabolism axis. Akkermansia is known for its ability to strengthen the gut lining, intestinal permeability, and stimulate GLP-1 production, an important tool when it comes to metabolism.

During this informative webinar, Colleen and Dr. Kolterman will discuss:
-The important role of the microbiome in the gut-metabolism axis
-Emerging research on Akkermansia and other novel probiotic strains on metabolic health
-New data on the impact of Akkermansia on food cravings

Details About the Webinar

Cost: Free

About the Speakers

1689089506-d98d352876af30fd Colleen Cutcliffe, PhD
Chief Executive Officer and co-founder of Pendulum

Colleen Cutcliffe has more than 20 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Prior to starting Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. Colleen completed her postdoctoral studies at Northwestern’s Children’s Memorial Hospital. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.

1689089710-8ed761194f2df580 Orville Kolterman, MD
Chief Medical Officer at Pendulum

Orville Kolterman has been the Chief Medical Officer at Pendulum since its launch. He is also an Adjunct Professor of Medicine at the University of California, San Diego. Orville has held a successful and distinguished 40 year medical career. During his 20 year tenure at Amylin, Orville served as the Chief Medical Officer, creating two of the most successful drugs, SYMLIN and BYETTA, which are among the most widely used diabetes drugs today. Before Amylin, Orville was the Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California Medical Center. Following graduation from the University of Kansas with a B.A. degree, Orville received a medical degree from Stanford University. He then completed his medical internship and residency at the University of Chicago prior to returning to Stanford for specialty training in Endocrinology and Metabolism.

First Name*

Last Name*

Email Address*

Zip Code*

What type of practitioner are you?*